Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €68.21 EUR
Change Today -0.418 / -0.61%
Volume 618.9K
FME On Other Exchanges
Symbol
Exchange
OTC US
Xetra
Munich
New York
Mexico
As of 3:55 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

fresenius medical care ag & (FME) Snapshot

Open
€68.91
Previous Close
€68.63
Day High
€69.00
Day Low
€67.27
52 Week High
04/14/15 - €82.32
52 Week Low
10/16/14 - €50.75
Market Cap
21.3B
Average Volume 10 Days
947.4K
EPS TTM
€3.48
Shares Outstanding
312.2M
EX-Date
05/20/15
P/E TM
21.9x
Dividend
€0.78
Dividend Yield
1.14%
Current Stock Chart for FRESENIUS MEDICAL CARE AG & (FME)

Related News

No related news articles were found.

fresenius medical care ag & (FME) Related Businessweek News

No Related Businessweek News Found

fresenius medical care ag & (FME) Details

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care services related to the dialysis treatment a patient receives with end stage renal disease (ESRD); and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of 3,361 outpatient dialysis clinics in approximately 45 countries worldwide; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure. The company also provides pharmacy services, such as delivery and supply of renal medications to patients at homes or to dialysis clinics directly; vascular, cardiovascular, and endovascular specialty services; and offers products for the treatment of ESRD. In addition, it offers laboratory services that include blood, urine, and other bodily fluid testing services; and hemodialysis (HD) machines, modular components for dialysis machines, polysulfone dialyzers, bloodlines, HD solutions and concentrates, needles, connectors, machines for water treatment, data administration systems, dialysis chairs, phosphate binders, iron products, and other renal drug products. Further, the company provides peritoneal dialysis systems and solutions for continuous ambulatory peritoneal dialysis and automated peritoneal dialysis; and adsorbers, which are filters used in other extracorporeal therapies; and distributes specific instruments for vascular access, as well as other supplies, such as bandages, clamps, and injections. The company sells its products to clinics, hospitals, and specialized treatment clinics through local sales forces, independent distributors, dealers, and sales agents. The company was founded in 1996 and is headquartered in Bad Homburg, Germany.

102,893 Employees
Last Reported Date: 07/30/15
Founded in 1996

fresenius medical care ag & (FME) Top Compensated Officers

Chairman of the Management Board for Freseniu...
Total Annual Compensation: $2.2M
Chief Financial Officer of Fresenius Medical ...
Total Annual Compensation: $1.3M
Chief Executive Officer of Fresenius Medical ...
Total Annual Compensation: $1.5M
Chief Executive Officer of Asia Pacific Divis...
Total Annual Compensation: $1.2M
Chief Executive Officer of Global Manufacturi...
Total Annual Compensation: $931.0K
Compensation as of Fiscal Year 2014.

fresenius medical care ag & (FME) Key Developments

Fresenius Medical Care Ag & Co. KGaA Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Year 2015 and 2016

Fresenius Medical Care AG & Co. KGaA reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total net revenues were $3,454 million against $3,014 million a year ago. Operating income (EBIT) was $547 million against $556 million a year ago. Income before taxes was $445 million against $458 million a year ago. Net income attributable to shareholders of the company was $241 million against $234 million a year ago. EBITDA was $728 million against $725 million a year ago. Basic earnings per share were $0.79 against $0.77 a year ago. Net cash provided by operating activities was $385 million against $449 million a year ago. Purchases of property, plant and equipment was $217 million against $220 million a year ago. For the six months, the company reported total net revenues were $8,159 million against $7,398 million a year ago. Operating income (EBIT) was $1,051 million against $1,001 million a year ago. Income before taxes was $847 million against $806 million a year ago. Net income attributable to shareholders of the company was $450 million against $439 million a year ago. EBITDA was $1,408 million against $1,337 million a year ago. Basic earnings per share were $1.48 against $1.46 a year ago. Net cash provided by operating activities was $832 million against $562 million a year ago. Purchases of property, plant and equipment was $418 million against $419 million a year ago. A total of $66 million in cash was spent for acquisitions and investments, net of divestitures.  For the year 2015 outlook the company expects revenue to grow at 5% to 7%, which at constant currency is a growth rate of 10 to 12%. Net income attributable to shareholders of the company is expected to increase by 0% to 5% in 2015. The company expects to spend around $1.0 billion on capital expenditures and around $400 million on acquisitions in 2015. For the full year, the company expects the tax rate to be in range of 33% to 34%. For the 2016 projections, the company expects revenue to increase around 7% to 10% against previously expected to be 9% to 12%. This is due to the fact that the company expects some of the initiatives in Care Coordination operations to be delayed into the following years. The net income attributable to shareholders of the company is still expected to grow by 15% to 20% is unchanged.

Fresenius Medical Care To Sell Venezuela Dialysis Service Unit

Fresenius Medical Care AG & Co. KGAA (DB:FME) is planning to sell its Venezuela dialysis service business, to incur $30 million loss.

Fresenius Medical Care Mulls Acquisitions

Fresenius Medical Care AG & Co. KGAA (DB:FME) is seeking acquisitions. Fresenius Medical Care said in second quarter 2015 results, “The company expects to spend around $1.0 billion on capital expenditures and around $400 million on acquisitions in 2015.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FME:GR €68.21 EUR -0.418

FME Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $38.75 USD +0.16
Becton Dickinson and Co $142.83 USD -0.12
DaVita HealthCare Partners Inc $76.29 USD -0.36
Mylan NV $50.37 USD -1.12
Toray Industries Inc ¥1,089 JPY +39.00
View Industry Companies
 

Industry Analysis

FME

Industry Average

Valuation FME Industry Range
Price/Earnings 22.2x
Price/Sales 1.4x
Price/Book 2.5x
Price/Cash Flow 22.8x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FRESENIUS MEDICAL CARE AG &, please visit www.fmc-ag.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.